Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02865668 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin XR Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants
A Phase 1 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
NCT02865668 is a Phase 1 study that has completed, run by Janssen Research & Development. The registered enrollment target is 44 participants.
The verdict
NCT02865668, a Phase 1 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate bioequivalence of the metformin component of the Fixed Dose Combination (FDC) tablet compared with the metformin Extended Release (XR) tablet coadministered with canagliflozin in healthy fed and fasted participants.
Interventions
- DRUG Canagliflozin
- DRUG Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC]
- DRUG Metformin Extended Release (XR)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2016-08 |
| Est. Completion | 2016-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02865668
The ClinicalTrials.gov registry entry for NCT02865668 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Canagliflozin is the first listed.
NCT02865668 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02865668 about?
NCT02865668 is a clinical study titled "A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin XR Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants". The purpose of this study is to evaluate bioequivalence of the metformin component of the Fixed Dose Combination (FDC) tablet compared with the metformin Extended Release (XR) tablet coadministered with canagliflozin in healthy fed and fasted participants.
What is the current status of trial NCT02865668?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2016-08. Estimated completion is 2016-10.
What interventions are being tested in trial NCT02865668?
The interventions under investigation include: Canagliflozin (DRUG), Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC] (DRUG), Metformin Extended Release (XR) (DRUG).
Who is sponsoring clinical trial NCT02865668?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.